Oxford University Press and the Chinese Antibody Society are pleased to announce their new partnership to launch the journal Antibody Therapeutics this spring.
A peer-reviewed, online, open access journal, Antibody Therapeutics provides a forum for the publication of the latest advances and challenges in the discovery, research, development, manufacturing, and methodology of therapeutic antibodies for the global scientific community.
Topics include target and antibody discovery, mechanistic research, new technologies and methods, manufacturing, clinical trials, regulation, policies, and more. Antibody Therapeutics article types include original research, reviews, cutting-edge technologies, new methods, news, interviews, and meeting highlights.
"It's our society's great honor to partner with reputed Oxford University Press in publication of the new journal. With over 1,200 registered members worldwide, our growing society will fully support the journal in many ways. I have strong confidence in the bright future of the journal, considering the support from the prestigious editorial board members of the journal, in particular the Editor-In-Chief Prof. Mitchell Ho." said Chinese Antibody Society President Shouye Wang.
Alison Denby, publishing director for Oxford Journals, said, "We are looking forward to launching Antibody Therapeutics in 2018. This area of study requires an open access journal with a strong support team, and we see that in our partnership with the Chinese Antibody Society. CAS is an engaged, dedicated group and we are committed to working together for this journal's success."
The journal is currently accepting submissions and plans to publish its first issue in 2018.
###
The Chinese Antibody Society aims to bring together industry leaders, healthcare providers, researchers, academics, and investors to connect and collaborate on the discovery, development, manufacturing, and marketing of therapeutic antibodies. Through its programs and services, the CAS serves as a platform fostering communication and collaboration among its members worldwide, in particular those in China and U.S. It also functions as a bridge to accelerate the approval by international regulatory agencies and marketing of antibody-based therapeutics developed in China.
Oxford Journals is a division of Oxford University Press, which publishes over 400 academic and research journals covering a broad range of subject areas, two thirds of which are published in collaboration with learned societies and other international organizations. Oxford Journals has been publishing journals for more than a century and, as part of the world's largest university press, has more than 500 years of publishing expertise behind it.